Stockreport

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT- [Read more]